ProShares Ultra Silver ETF vs Citius Pharmaceuticals Inc — how do they compare? ProShares Ultra Silver ETF trades at $81.45, while Citius Pharmaceuticals Inc trades at $0.76 (market cap $20.01M). The key difference: Citius Pharmaceuticals Inc is trading nearer its 52-week high, ProShares Ultra Silver ETF nearer its low. Which is the better fit depends on your goals.
| AGQ | CTXR | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $400.47 | $1.82 |
52-Week Low | $49.73 | $0.48 |
Market Cap | — | $20.01M |
Enterprise Value | — | $16.23M |
Signals from Pluang's Aura AI — not financial advice
AGQ, a leveraged silver ETF, trades at $81.11, down 0.94% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights volatility, with articles noting a 9.39% surge on silver rallies but structural decay risks from daily-reset leverage. Financial ratios are unavailable as AGQ is an ETF tracking silver futures, not a company with fundamentals.
The outlook hinges on silver price momentum, offering amplified gains but high risk from leverage decay and silver volatility. Key risks include underperformance versus unlevered ETFs and sharp declines during silver sell-offs, as seen in a 16% drop in June 2026. Investors should weigh silver's bullish trend against ETF-specific drawbacks.
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
Trailing returns across standard periods
Latest headlines on both assets
AGQ is a leveraged ETF that seeks daily investment results corresponding to two times (2x) the daily performance of silver bullion. It is designed for investors seeking magnified short-term exposure to silver prices.
Read more on AGQ →Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →